Zmax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6984403 PF PRISM CV Azithromycin dosage forms with reduced side effects
Feb, 2024

(4 months from now)

US7887844 PF PRISM CV Multiparticulate crystalline drug compositions having controlled release profiles
Feb, 2024

(4 months from now)

Zmax is owned by Pf Prism Cv.

Zmax contains Azithromycin.

Zmax has a total of 2 drug patents out of which 0 drug patents have expired.

Zmax was authorised for market use on 10 June, 2005.

Zmax is available in for suspension, extended release;oral dosage forms.

Zmax can be used as method of treating bacterial infections.

The generics of Zmax are possible to be released after 14 February, 2024.

Drugs and Companies using AZITHROMYCIN ingredient

Market Authorisation Date: 10 June, 2005

Treatment: Method of treating bacterial infections


More Information on Dosage

ZMAX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic